We're pleased to announce that the ISSM will offer 10 scholarships to first-time attendees of the European Society of Sexual Medicine's School of Sexual Medicine to be held November 8 - 17, 2019 in Budapest, Hungary.

This annual program is intended for clinicians who wish to acquire the knowledge and skills necessary to practice in sexual medicine and clinical sexology.

Each scholarship covers the full registration fee, which includes tuition, meals, and accommodations.

Click here for more information on eligibility criteria and application instructions. Please note that all application materials must be submitted no later than June 3, 2019.

The U.S. Food and Drug Administration (FDA) has modified its boxed warning for Addyi (flibanserin), a drug used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. 

The safety labeling changes reflect studies on the interaction of Addyi and alcohol. 

"Specifically, the boxed warning, contraindication, warnings and precautions, and adverse reactions sections of labeling are being updated to reflect that women should discontinue drinking alcohol at least two hours before taking Addyi at bedtime or to skip the Addyi dose that evening. Women should not consume alcohol at least until the morning after taking Addyi at bedtime," the FDA said.

First approved by the FDA in 2015, Addyi works by balancing levels of neurotransmitters in the brain related to sexual desire.

Find out more.